Tick-borne relapsing fever (TBRF) is a zoonosis caused by spirochetes of the genus *Borrelia*. The arthropod vector is a soft tick of the genus *Ornithodoros*, which is endemic to America, Africa, Asia, the Near East and Middle East, and the Iberian Peninsula in Europe (1). In each region, a specific relationship exists between *Ornithodoros* spp. and *Borrelia* spp. To date, 23 TBRF-related *Borrelia* species have been confirmed, but additional species are proposed (2). *B. hispanica* is the primary TBRF-related *Borrelia* species identified in Spain (3,4), where it is transmitted mainly through the bite of *O. erraticus* ticks (5) but also can be transmitted by *O. occidentalis* ticks (4). *B. hispanica* also has been found in Portugal (6), Morocco (4,7,8), and Tunisia (4).

TBRF is a notifiable disease in Spain and is considered endemic in Spain and Andalusia, specifically in southern Spain. During 2003–2017, a total of 85 TBRF cases were reported (9), which represented 11% of all reported tickborne diseases, including Lyme disease and Mediterranean exanthematic fever. The areas in Andalusia most affected by TBRF were Seville (67%), Malaga (17.6%), and Cordoba (10.6%). However, the incidence of TBRF could be underestimated because it is difficult to diagnose and because patients and healthcare professionals suspect it less frequently than other tickborne diseases (9).

Serologic tests are not useful in diagnosing TBRF because of the antigenic variation of the bacterial variable membrane proteins and cross-reactions with other diseases, such as syphilis and Lyme disease. Hence, these tests are not recommended for routine diagnosis (10). Other diagnostic methods, such as molecular detection or isolation of *Borrelia* in special media, usually are available only in reference centers. Demonstration of *Borrelia* in peripheral blood is the definitive method of diagnosis but requires a high degree of experience (11).

The pathogenesis of TBRF ranges from a mild to a severe disease, depending on the host and the infecting *Borrelia* species (12), and the disease has a broad spectrum of clinical signs and symptoms. Within a few hours of receiving the first dose of antimicrobial drugs to treat TBRF, patients can experience Jarisch-Herxheimer reaction (JHR), an acute exacerbation of symptoms (13).

We studied cases of TBRF diagnosed during 1994–2016 at La Merced Hospital, located in southern Spain. Our aim was to enhance knowledge of TBRF epidemiology, clinical and treatment aspects, and risk factors for JHR. In addition, we studied the relationship of this disease and its associated environmental factors.

**Methods**

**Patients, Study Design, and Setting**

We conducted an observational cross-sectional study of all confirmed cases of TBRF diagnosed at La Merced Hospital, a 240-bed public hospital, in Osuna, Spain.
We included all patients diagnosed with ≥1 episode of TBRF during December 1994–December 2016. The area of southern Spain served by this healthcare facility (Figure 1) has a population of ≈174,000.

Diagnosis of TBRF
Diagnosis of TBRF was made by visualization of Borrelia spp. in thick or thin blood smears stained with 10% Giemsa and then examined by optical microscopy. We extracted blood during febrile attacks. Spirochetemia was quantified by light microscopy, at 1,000× magnification, as follows: >5 spirochetes in each field of vision was 3+; 1–5 spirochetes in each field of vision was 2+; <1 spirochete in each field of vision was 1+. During 2013–2014, we sent Borrelia–positive samples to the National Microbiology Center (Madrid, Spain) for species identification by multiplex PCR.

Variables and Definitions
The principal variable was confirmation of TBRF by direct diagnosis. Epidemiologic variables collected included patient age, sex, town of origin, occupation, hobbies, contact with rodents. Other variables recorded were those associated with underlying conditions, such as diabetes mellitus, arterial hypertension, chronic obstructive pulmonary disease, chronic liver disease, chronic kidney disease, cancer, neurologic disease, chronic digestive pathology, cutaneous ulcer, chronic heart failure, HIV infection, transplant recipient, and pregnancy. In addition, variables related to TBRF were recorded, including date of diagnosis, symptoms, remembered antecedent of tick bite, duration of clinical symptoms before diagnosis, main clinical signs, hospitalization, treatment, JHR, and outcome. We analyzed determinants gathered in blood samples, including hemogram and coagulation; serum, including basic biochemistry, C-reactive protein, and liver, renal, and cardiac profiles; and cerebrospinal fluid (CSF), including leukocyte count, percentage of lymphocytes, glucose, and proteins. We used the first determinant collected after symptom onset.

Meteorologic Conditions
We obtained monthly meteorologic statistics from the records of La Agencia Estatal de Meteorología (http://www.aemet.es/en/portada) of Spain during 1994–2016. We included mean temperature (°C) and percent humidity collected on day 7, 13, and 18 each month at the weather station at Morón de la Frontera (37°.9′49.8767″N, 5°.36′40.5219″W). The station is 87 m above sea level and 40 km from Osuna (Figure 1).

Statistical Methods
We described cases of TBRF by using epidemiologic and clinical variables and investigated the relationship
between environmental factors and TBRF incidence by using a mixed model. We performed calculations by using R software (https://www.r-project.org). We also investigated the risk factors of JHR by performing univariate comparisons of patients who experienced JHR and those who did not by using \( \chi^2 \) or Fisher exact test, as needed, for categorical variables and Student \( t \)-test or Mann-Whitney \( U \)-test for continuous variables, as appropriate. To control for confounding factors, we performed a multivariate logistic regression analysis by using JHR as the dependent variable. We performed statistical analysis by using SPSS 21.0 (IBM, https://www.ibm.com). We express continuous variables as median and interquartile range (IQR) and categorical variables as number and percent.

**Ethics Approval**

The study was designed and performed according to the World Health Association’s Declaration of Helsinki (https://www.wma.net) and was approved by the ethics committee of La Merced Hospital. Because it was a retrospective study, consecutive blinded case numbers were assigned for medical histories taken from patient records to ensure a safe dissociation and prevent identification of patients included.

**Results**

**Incidence of TBRF**

We calculated the annual incidence of TBRF cases by analyzing data from 98 case-patients included in our final cohort (Figure 2). TBRF incidence increased over the study period and showed considerable variability between years. The highest incidence rates of TBRF occurred in 2015 (8.69 cases/100,000 persons), 2011 (6.31 cases/100,000 persons), and 2014 (5.77 cases/100,000 persons). Most cases of TBRF were diagnosed during June–November.

**Diagnosis of TBRF**

All TBRF cases in our series were diagnosed by direct visualization of *Borrelia* in blood samples. Spirochetaemia quantification was either 1+ or 2+. Blood samples were negative 1–2 days after initial *Borrelia* visualization. Samples collected from 12 patients during 2013–2014 were sent to the National Microbiology Center, where the bacteria species was identified as *B. hispanica* by multiplex PCR targeting the 16S rRNA gene.

**Clinical, Analytical, and Therapeutic Features of TBRF Cases**

Among 98 patients with TBRF in our cohort, 55 (56.1%) were men and 43 (43.9%) were women (Table 1), 2 of whom were pregnant. Our data agree with the prevalence of TBRF in young persons; 19% of patients in our cohort were <14 years of age (data not shown). Of note, 80% of case-patients lived in a rural environment, and only 17 (17.3%) reported previous known contact with ticks. In most cases, TBRF diagnosis was made in the emergency department. Median time between the onset of symptoms and diagnosis was 3 days (IQR 2–5 days).

The most common clinical symptoms were fever in 99% of cases, headache in 59%, vomiting in 34.7%, and arthralgias in 30% (Table 2). A lumbar puncture was performed on 12 patients; 5 had no neck stiffness, deterioration of consciousness, or signs of Kernig and Brudzinski, but because they had fever, vomiting, and intense headaches, clinicians decided to extract CSF. Lymphocytic meningitis with moderate to high pleocytosis of mononuclear predominance, elevated proteins, and normal glucose were noted in CSF from...
was affected in 1997 and 2005, and 1 in a hiker who was affected in 2011 and 2013.

We noted 5 clusters of TBRF; 4 occurred in family groups, and 1 involved persons with a common social activity. A 2015 cluster involved 5 family members, a 2014 cluster affected 2 family members, and 3 family members were involved in each cluster noted in 2004 and 2011. Another 2014 cluster occurred among 3 persons who all reported hunting in Osuna, Seville.

**Correlation between Meteorologic Conditions and TBRF Incidence**

We established a mixed model in which the temperature, humidity, and month have been established as fixed effects and the year as a random competent. When applying the different models, we found that humidity had little effect and that the risk for tick bites was dependent on the temperature and month. Bites were more frequent during summer and autumn months, when higher temperatures were recorded.

**Risk Factors for JHR**

Of 98 TBRF cases, we analyzed JHR risk factors for 79 patients, 8 (10.1%) of whom had JHR symptoms, including chills, worsening fever, tachycardia, hypotension, and anxiety, a few hours after starting antimicrobial drug treatment. In our analysis, male sex was a risk factor (8.9%) for JHR compared with female sex (1.3%; \( p = 0.13 \)) and length of admission (median 5 days; IQR 4–7 days) was a statistically significant risk factor (8.9%) for JHR compared with female sex (1.3%; \( p = 0.13 \)). We saw no relationship between specific antimicrobial drugs and JHR. In multivariable analysis, we found no variables independently associated with JHR (Table 4).

**Discussion**

We analyzed 98 cases of TBRF identified during a 23-year period from a *Borrelia*-endemic area of Spain. The highest incidence rates were in 2015 (8.69/100,000 persons), 2011 (6.31/100,000 persons), and 2014 (5.77/100,000 persons); no cases were reported in 1995, 2001, or 2012 (Figure 2). The highest number of cases originated in Osuna (43 cases), Ecija (21 cases), La Lantejuela (8 cases), Marchena (5 cases), and La Puebla de Cazalla (4 cases); other areas had <5 cases (Figure 1). The TBRF incidence trended upward during the study period, probably because of increased awareness of the disease. The peaks observed in 2015, 2014, and 2011 can be justified in part by outbreaks of TBRF among persons in family groups or participating in same social activity. We do not know why years of greater incidence are interspersed among others of little (2009, 2010) or no (2012) incidence. We have not

### Table 1. Characteristics of 98 patients with tick-borne relapsing fever, Spain*

| Variable                        | Value          |
|---------------------------------|----------------|
| Median age, y (IQR)             | 29 (17–46)     |
| Sex                             |                |
| M                               | 55 (56.1)      |
| F                               | 43 (43.9)      |
| Town of residence               |                |
| Osuna                           | 40 (40.8)      |
| Ecija                           | 20 (20.4)      |
| Other                           | 38 (38.8)      |
| Risk activities                 |                |
| Farming                         | 15 (15.3)      |
| Hiking                          | 10 (10.2)      |
| Hunting                         | 3 (3.1)        |
| Contact with rodents            | 13 (13.3)      |
| Tick bite                       | 17 (17.3)      |
| JHR, n = 79                     | 8 (10.1)       |
| Median time before diagnosis, d (IQR) | 3 (2–5) |
| Hospitalized                    | 56 (57.1)      |
| Median length of hospital admission, d (IQR) | 5 (4–6) |
| Antimicrobial drug treatment    |                |
| Tetracycline                    | 79 (80.6)      |
| Macrolides                      | 18 (18.4)      |
| Cephalosporin                   | 9 (9.2)        |
| Penicillin G                    | 2 (2)          |
| Duration of antimicrobial therapy, d (IQR) | 10 (7–14) |
| Death                           | 0              |

*Values are no. (%) except as indicated. IQR, interquartile range; JHR, Jarisch-Herxheimer reaction.

†Except where noted.
sampled Ornithodoros ticks to evaluate densities and infection rates, nor have we collected samples from small mammals to investigate the reservoir of Borrelia spp.

We studied climatic conditions during 1994–2016 and identified a direct correlation of TBRF incidence with increased temperatures during the summer and autumn. Higher TBRF incidence rates during the warmest months can be explained by increased activity of the tick vectors and increased exposure of the general population to those vectors, both of which increase the possibility of tick bites in humans (8).

We used Giemsa staining of thin and thick blood films to identify Borrelia, but a density of $\geq 10^5$ spirochetes/1 mL of blood is needed for definitive diagnosis in thick films and $\geq 10^6$ spirochetes/1 mL of blood for thin films and microscopic visualization is not a reliable diagnostic method for TBRF (13). Larsson et al. (14) suggested the sensitivity of the method could be increased by performing a double centrifugation of the blood sample inoculated in a tube with heparin. The application of phase contrast or dark field microscopy directly on a 10× blood dilution also could be useful for cases of spirochetemia (10). Where it is technically possible, PCR is replacing microscopic visualization for diagnosis (7,15,16), but Hospital de la Merced is a small hospital in a rural area and does not have in-house PCR resources.

The most prevalent, and probably the only, Borrelia species in the environment in this area is B. hispanica, which usually causes mild infection. Patients with TBRF in our hospital had mainly nonspecific clinical signs, such as fever and headache, and none died. Meningitis and facial palsy are the most frequent neurologic complications associated with TBRF (17). Only 3 (3.06%) patients in our series had lymphocytic meningitis, and we did not observe any instances of facial palsy. However, meningitis and encephalitis have been reported in infections caused by other Borrelia species, including B. crocidurae (18), B. duttoni, and B. turicatae (17).

We did not observe additional clinical complications in pregnant women, but Rustenhoven-Sappan et al. (19) reported that pregnant women have higher spirochete loads and more severe symptoms than women who are not pregnant. Some evidence also suggests that spirochetes can cross the placenta and cause neonatal relapsing fever (20). However, we only had 2 TBRF cases in pregnant women, so the lack of clinical complications in this group likely can be attributed to the small sample size in our series.

The most common abnormality in blood cell count we noted in laboratory findings was thrombocytopenia, especially during the early stage of infection, with a median of 63,500 platelets/mm$^3$ in the hemogram. Thrombocytopenia has been reported in B. crocidurae (12), B. hermsii (21), and B. hispanica (22–24) infections, but not with B. burgdorferi (25). Thrombocytopenia could be explained by the phenomenon of bacteria binding directly to platelets during the infection, which results in increased platelet destruction, prolonged bleeding, or endothelial injury, the degree of which correlates with the degree of spirochetemia (21).

We observed anemia in 33% of patients at TBRF diagnosis with hemoglobin values $<11.8$ g/dL and hematocrits $<35\%$, likely caused by erythrocyte

| Variable                                      | Value     |
|-----------------------------------------------|-----------|
| Symptoms                                      |           |
| Fever $>38.5^\circ C$                         | 97 (99)   |
| Headache                                      | 58 (59)   |
| Vomiting                                      | 34 (34.7) |
| Arthralgia                                    | 29 (30)   |
| Abdominal pain                                | 28 (28.6) |
| Myalgia                                       | 28 (28.6) |
| Chills                                        | 23 (23.6) |
| Diarrhea                                      | 6 (6.1)   |
| Signs                                          |           |
| Meningeal signs                               | 7 (7.1)   |
| Splenomegaly                                  | 7 (7.1)   |
| Hepatomegaly                                  | 6 (6.1)   |
| Exanthema                                     | 4 (4.1)   |
| Jaundice                                      | 3 (3.1)   |
| Petechiae                                     | 2 (2)     |
| Conjunctival injection                        | 2 (2)     |
| Analytical findings                           |           |
| Median platelet count, $\times 10^9$/mm$^3$ (IQR) | 63.5 (45.7–87.5) |
| Thrombocytopenia, platelets                   | 91 (92.9) |
| $<13 \times 10^9$/mm$^3$                      |           |
| Hemoglobin, g/dL (IQR)                        | 13.1 (11.8–14.2) |
| Anemia                                        | 32 (32.6) |
| Leukocytes, $\times 10^9$/mm$^3$ (IQR)        | 7.9 (6.6–9.8) |
| Leukocytosis, $>1,500$/mm$^3$                 | 10 (10.2) |
| Neutrophils, median (IQR)                     | 79 (74.5–86.4) |
| Neutrophilia, neutrophils $>65\%$             | 91 (92.9) |
| Prothrombin activity, median (IQR)            | 77 (70–87) |
| Decreased prothrombin activity, $<70\%$       | 7 (13.7)  |
| Median INR (IQR)                              | 1.2 (1.1–1.3) |
| INR elevation, $>1.51$                        | 7 (13.7)  |
| SGOT, U/L (IQR)                               | 25 (20–35) |
| SGOT elevation, $>37$ U/L                     | 15 (21.7) |
| SGPT, U/L (IQR)                               | 25 (17–41) |
| SGPT elevation, $>40$ U/L                     | 10 (23.3) |
| Total bilirubin, mg/dL (IQR)                  | 1.1 (0.6–1.9) |
| Elevated bilirubin, $>1.2$ mg/dL              | 37 (37.8) |
| Lactate dehydrogenase, U/L (IQR)              | 397.5 (320.7–481.7) |
| Elevated LDH, $>460$ U/L                      | 16 (30.8) |
| Creatinine, mg/dL (IQR)                       | 0.94 (0.79–1.15) |
| Creatinine elevation, $>1.2$ mg/dL            | 15 (15.3) |
| Creatine kinase, U/L (IQR)                    | 41 (27–75) |
| Elevated creatine kinase, $>195$ U/L          | 3 (14)    |
| C-reactive protein, mg/L (IQR)                | 254.5 (218.2–335.3) |
| Elevated C-reactive protein, $>5$ mg/L        | 98 (100)  |

*Values are no. (%) except as indicated. INR, international normalized ratio; IQR, interquartile range; SGOT, serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase.
SYNOPSIS

Table 3. Findings from cerebrospinal fluid collected from 12 patients with tick-borne relapsing fever, Spain

| Case no. | Patient age, y | Protein, mg/dL | Glucose, mg/dL | Leukocytes/μL | Lymphocytes, % | Meningitis |
|---------|----------------|----------------|----------------|---------------|----------------|------------|
| 1       | 50             | 174            | 48             | 1,271         | 57             | Y          |
| 2       | 6              | 130            | 61             | 1,760         | 90             | Y          |
| 3       | 21             | 91             | 49             | 521           | 90             | Y          |
| 4       | 17             | 74             | 62             | 0             | 0              | N          |
| 5       | 5              | 32             | 47             | 130           | 80             | N          |
| 6       | 42             | 23             | 74             | 1             | 100            | N          |
| 7       | 14             | 20             | 57             | 0             | 0              | N          |
| 8       | 19             | 20             | 62             | 4             | 75             | N          |
| 9       | 28             | 20             | 49             | 4             | 75             | N          |
| 10      | 26             | 19             | 60             | 0             | 0              | N          |
| 11      | 32             | 13             | 64             | 1             | 100            | N          |
| 12      | 12             | 12             | 78             | 3             | 100            | N          |

The aggregation of red blood cells around *B. hispanica* has been observed in vitro by Guo et al. (26) and has been described in infections with *B. duttonii* and *B. coriaceae* (26). Erythrocyte rosetting also has been reported by Shamaei-Tousi et al. (12) in an animal model infected with the *B. crocidurae*.

We also detected neutrophilia that did not produce leucocytosis because of compensatory lymphopenia. López et al. (27) studied an animal model with Rhesus macaques infected with *B. turicatae* and observed notable changes in the differential leukocyte count. They found a relative increase in the neutrophil percentage for several days after leukopenia and mild increases in monocytes several days after the initial episode of leukopenia. They noted these abnormalities to some degree in all animals studied, and the neutrophilia coincided with spirochetemia (27).

Another finding that deserves attention is pancytopenia, a potentially serious complication, which we observed in 5% of TBRF cases. Fortunately, severe pancytopenia is a rare complication described in only a few cases (13,24).

All patients in our study demonstrated known TBRF biochemical alterations in the acute phase, including high levels of C-reactive protein (22–24), mild hypertransaminasemia (13,28,29), and hyperbilirubinemia (29,30). Less frequently, elevated lactate dehydrogenase and creatinine kinase also have been reported (22); we observed elevated lactate dehydrogenase in 31% of cases in our study and elevated creatinine kinase in 15%.

*Borrelia* spirochetes are susceptible to penicillin and other β-lactam antimicrobial drugs and to tetracyclines and macrolides. Most experts recommend a dose of 100 mg doxycycline twice a day or 500 mg tetracycline four times a day for 7–14 days (1). Erythromycin or chloramphenicol are the most used alternatives (1). Parenteral therapy with ceftriaxone is recommended for patients with central nervous system involvement or severe multisystem disease (1).

Fluoroquinolones are not recommended for treating patients with TBRF (29). In our experience, we treated patients with some of the recommended regimens over a median of 10 days, and they had adequate, early responses to treatment. A shorter regimen might be equally effective for treating TBRF.

We observed JHR in 10.1% of patients. Our patients did not have severe JHR, but severe cases have been reported (31), including elevated cardiac troponin in pregnant women (23,28) and, more frequently, in children (19,23). However, neither of the 2 pregnant women in our TBRF cohort developed JHR.

Immunity to *B. hispanica* after infection is not permanent, so patients can be reinfected later. We detected 2 cases of reinfection. Reinfections with *B. crocidurae* also have been observed in patients in Senegal (32), demonstrating the importance of informing patients of this aspect of TBRF.

In conclusion, we analyzed epidemiologic data of 98 TBRF cases diagnosed in southern Spain during 1994–2016. In addition to information on the *Borrelia* life cycle, we report clinical signs, laboratory findings, prognosis, complications, and TBRF diagnosis, in patients at a rural hospital. Because clinical signs and symptoms of TBRF cover a wide range and incidence is low, clinicians have a low suspicion index for this disease. The most frequent symptoms are fever and headache and the most frequent analytical alterations are thrombocytopenia and neutrophilia without leucocytosis, in addition to the elevated C-reactive protein during the acute phase. TBRF occurs in rural environments, mainly in summer and autumn. We saw no evidence of a climate-associated increase in infection risk over the 23-year period. TBRF usually is not a severe disease in patients in this region of Spain, and they respond well to treatment. Because the spirochetemia phase is short and laboratory diagnosis is exclusively dependent on the observer, we believe TBRF is underdiagnosed, even in areas where suspicion should be relatively high. Addition of routine molecular
techniques to detect spirochetes could eliminate these diagnostic doubts in rural areas.

**About the Author**

Dr. Domínguez is a clinical microbiologist at La Merced Hospital, Osuna, Seville, Spain. Her primary research interests are borreliosis and epidemiology.

**Table 4. Factors associated with risk for JHR among 79 cases of tick-borne relapsing fever, Spain**

| Variable                        | Value                  | p value†   | Adjusted OR (95% CI) | p value‡   |
|---------------------------------|------------------------|------------|----------------------|------------|
| Sex                             |                        | 0.13       | NS                   |            |
| F                               | 1 (1.3)                |            |                      |            |
| M                               | 7 (8.9)                |            |                      |            |
| Median age, y (IQR)             |                        | 0.86       | NS                   |            |
| Y                               | 28.6 (17.3–46.3)       |            |                      |            |
| N                               | 25.5 (18.9–48.7)       |            |                      |            |
| Rural environment               |                        | 0.57       | NS                   |            |
| Y                               | 7 (8.9)                |            |                      |            |
| N                               | 1 (1.3)                |            |                      |            |
| Contact with rodents            |                        | 0.11       | NS                   |            |
| Y                               | 3 (3.8)                |            |                      |            |
| N                               | 5 (6.3)                |            |                      |            |
| Hepatomegaly                    |                        | 0.46       | NS                   |            |
| Y                               | 0 (0.0)                |            |                      |            |
| N                               | 8 (10.1)               |            |                      |            |
| Splenomegaly                    |                        | 0.49       | NS                   |            |
| Y                               | 1 (1.3)                |            |                      |            |
| N                               | 7 (8.9)                |            |                      |            |
| Jaundice                        |                        | 0.9        | NS                   |            |
| Y                               | 0 (0.0)                |            |                      |            |
| N                               | 8 (10.1)               |            |                      |            |
| Petechiae                       |                        | 0.9        | NS                   |            |
| Y                               | 0 (0.0)                |            |                      |            |
| N                               | 8 (10.1)               |            |                      |            |
| Meningeal signs                 |                        | 0.9        | NS                   |            |
| Y                               | 0 (0.0)                |            |                      |            |
| N                               | 8 (10.1)               |            |                      |            |
| Exanthema                       |                        | 0.28       | NS                   |            |
| Y                               | 1 (1.3)                |            |                      |            |
| N                               | 7 (8.9)                |            |                      |            |
| Tick bite                       |                        | 0.17       | NS                   |            |
| Y                               | 3 (3.8)                |            |                      |            |
| N                               | 5 (6.3)                |            |                      |            |
| Tetracycline                    |                        | 0.54       | NS                   |            |
| Y                               | 7 (8.9)                |            |                      |            |
| N                               | 1 (1.3)                |            |                      |            |
| Cephalosporin                   |                        | 0.31       | NS                   |            |
| Y                               | 2 (2.5)                |            |                      |            |
| N                               | 6 (7.6)                |            |                      |            |
| Macrolides                      |                        | 0.35       | NS                   |            |
| Y                               | 1 (1.3)                |            |                      |            |
| N                               | 7 (8.9)                |            |                      |            |
| Median length of clinical signs |                        | 0.36       | NS                   |            |
| Y                               | 3 (2–5.8)              |            |                      |            |
| N                               | 3 (1.3–4)              |            |                      |            |
| Median length of hospital admission, d (IQR) |            | 0.004      | 0.56 (0.29–1.02)    | 0.057   |
| Y                               | 5 (4–7)                |            |                      |            |
| N                               | 3 (3–3.3)              |            |                      |            |
| Median duration of antimicrobial therapy, d (IQR) |            | 0.55       | NS                   |            |
| Y                               | 10 (8–14)              |            |                      |            |
| N                               | 10 (9–11.8)            |            |                      |            |

*Values are no. (%) patients with JHR except as indicated. IQR, interquartile range; JHR, Jarisch-Herxheimer reaction; NS, not statistically significant; OR, odds ratio.
†Univariate analysis calculated by using χ² or Fisher exact test.
‡Multivariate analysis calculated by using Student t-test or Mann-Whitney U-test.
§Values represent findings from 36 patients with known length of clinical signs.

**References**

1. Cutler SJ. Relapsing fever Borreliae: a global review. Clin Lab Med. 2015;35:847–65. https://doi.org/10.1016/j.cll.2015.07.001
2. Cutler SJ, Ruzic-Sabljic E, Potkonjak A. Emerging borreliae—expanding beyond Lyme borreliosis. Mol Cell Probes. 2017;31:22–7. https://doi.org/10.1016/j.mcp.2016.08.003
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 5, May 2020

SYNOPSIS

3. Toledo A, Anda P, Escudero R, Larsson C, Bergstrom S, Benach JL. Phylogenetic analysis of a virulent *Borrelia* species isolated from patients with relapsing fever. J Clin Microbiol. 2010;48:2484–9. https://doi.org/10.1128/JCM.00541-10

4. Trape JF, Diatta G, Arnathau C, Bitam I, Sarth M, Belghiti D, et al. The epidemiology and geographic distribution of relapsing fever borreliosis in West and North Africa, with a review of the *Ornithobacterium erraticus* complex (Acari: *Ixodida*). PLos One. 2013;8:e78473. https://doi.org/10.1371/journal.pone.0078473

5. Boinas F, Ribeiro R, Madeira S, Palma M, de Carvalho IL, Nuncio S, et al. The medical and veterinary role of *Ornithobacterium erraticus* complex ticks (Acari: *Ixodida*) on the Iberian Peninsula. J Vector Ecol. 2014;39:238–48. https://doi.org/10.1111/jvec.12098

6. Palma M, Lopes de Carvalho I, Figueiredo M, Amaro F, Boinas F, Cutler SJ, et al. *Borrelia hispanica* in *Ornithobacterium erraticus*, Portugal. Clin Microb Infect. 2012;18:696–701. https://doi.org/10.1111/j.1469-0691.2011.03623.x

7. Sarth M, Garnier M, Boudehouech N, Bouattour A, Rihani A, Hassar M, et al. *Borrelia hispanica* relapsing fever, Morocco. Emerg Infect Dis. 2009;15:1626–9. https://doi.org/10.3201/eid1510.090403

8. Diatta G, Souci D, Yaranon J, Arnathau C, Durand P, Chauvancy G, et al. Epidemiology of tick-borne borreliosis in Morocco. PLoS Negl Trop Dis. 2012;6:e1810. https://doi.org/10.1371/journal.pntd.0001810

9. Calderón Cid M, Fernández García MA, Enric Duran Pla E. Diseases transmitted by ticks in Andalusia [in Spanish]. SVEA Informe Semanal. 2018;23:1–2.

10. Larsson C, Andersson M, Bergström S. Current issues in laboratory diagnosis of relapsing fever borreliosis. Open Microbiol J. 2008;2:10–2. https://doi.org/10.2174/j.1469-0691.2004.01019.x

11. Brouqui P, Couetdic G, et al. Epidemiology of tick-borne relapsing fever *Borrelia crocidurae* in Morocco. *PLoS Negl Trop Dis*. 2013;7:e2042.

12. Hoekstra KA, Kelly MT. Maternal mortality in a rural Tanzanian hospital: fatal Jarisch-Herxheimer reaction in a case of relapsing fever in pregnancy. Trop Doct. 2013;43:138–41. https://doi.org/10.1177/004947513497477

13. Webster G, Schiffman JD, Dosanjh AS, Amieva MR, Gans HA, Sectish TC. Jarisch-Herxheimer reaction associated with ciprofloxacin administration for tick-borne relapsing fever. *J Infect Dis*. 2014;210:1639–48. https://doi.org/10.1093/infdis/jiu306

14. Laredo RM, Vázquez-Arroyo C, Barrón R, Martín E, Aragón J, Arribas L, et al. Relapsing fever in a 13-year-old child in Spain. J Pediatr Infect Dis. 2017;11:51. https://doi.org/10.1016/j.jpedinf.2017.02.001

15. Hoekstra KA, Kelly MT. Elevated troponin and Jarisch-Herxheimer reaction in tick-borne relapsing fever: a case report. Case Rep Infect Dis. 2011;2011:950314. https://doi.org/10.1155/2011/950314

16. Webster G, Schiffman JD, Dosanjh AS, Amieva MR, Gans HA, Sectish TC. Jarisch-Herxheimer reaction associated with ciprofloxacin administration for tick-borne relapsing fever. Pediatr Infect Dis J. 2002;21:571–3. https://doi.org/10.1097/00006454-200206000-00020

17. Kotlyar S. Tick-borne relapsing fever in Southwest Colorado: a case report. J Emerg Med. 2017;52:83–5. https://doi.org/10.1016/j.jemermed.2016.07.014

18. Larsson C, Bergström S, Siddle K, Nuncio S, et al. The isolates from patients with relapsing fever. *PLoS Negl Trop Dis*. 2013;7:e2042.

19. Rustenhoven-Spaan I, Melkert P, Nelsen E, van Roosmalen J, Stekelenburg J. Maternal mortality in a rural Tanzanian hospital: fatal Jarisch-Herxheimer reaction in a case of relapsing fever in pregnancy. Trop Doct. 2013;43:138–41. https://doi.org/10.1177/004947513497477

20. Larsson C, Andersson M, Guo BP, Nordstrand A, Hagerstrand I, Carlsson S, et al. Complications of pregnancy and transplacental transmission of relapsing-fever borreliosis. *J Infect Dis*. 2006;194:1367–74. https://doi.org/10.1086/508425

21. Alugupalli KR, Michelson AD, Joris I, Schwan TG, Hodivala-Dilke K, Hynes RO, et al. Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. Blood. 2003;102:2843–50. https://doi.org/10.1182/blood-2003-02-0426

22. Wyplosz B, Mhaila-Amrouch L, Baixench MT, Biegel ML, Berardi-Grassias L, Fontaine C, et al. Imported tickborne relapsing fever, France. Emerg Infect Dis. 2005;11:1801–3. https://doi.org/10.3201/eid1111.050616

23. García-Soler P, Núñez-Cuadros E, Milano-Manso G, Ruiz Sánchez P. Severe Jarisch-Herxheimer reaction in tick-borne relapsing fever [in Spanish]. Enferm Infec Microbiol Clin. 2011;29:710–1. https://doi.org/10.1016/j.jemic.2011.01.019

24. Leen I, Bruynyseels P, Mukadi BK, van Oort M, van den Akker M. A 13-year old girl with pancytopenia at the presentation of a *Borrelia hispanica* infection: a case report and review of the literature. J Med Case Reports. 2017;11:51. https://doi.org/10.1182/blood-2003-02-0426